Abstract:Background Heart transplantation (HTx) is a treatment option for patients with end-stage heart failure (HF) who remain symptomatic despite optimal medical therapy. There is a growing number of patients undergoing HTx. Non-alcoholic fatty liver disease (NAFLD) is known to increase the risk of adverse outcomes. At this moment, there is limited scientific evidence of clinical outcomes in HTx patients affected by NAFLD. Therefore, we sought to investigate this population. Methods We queried NIS between 2017-2020 for adult patients who were hospitalized for HTx and had NAFLD. The primary outcome was inpatient mortality. The secondary outcomes were cardiogenic shock, cardiac arrest, gastrointestinal bleeding (GIB), invasive mechanical ventilation, length of stay (LOS) and total hospital cost. Multivariable logistic and Poisson regression analyses were used to estimate clinical outcomes. p-value < 0.05 was significant. Results There were 11,795 hospitalizations for HTx, of which 1,215 (10.3%) had NAFLD. NAFLD and non-NAFLD cohorts were with mean age of 51.0 vs. 54.3 yrs; males 74% vs 71.5%; Caucasians 61.7% vs 58.4%; HF 94.6% vs 96.2%; LVAD 14.8% vs 19.1%, obesity 11.1% vs 12.5%; HLD 22.6% vs 37.1%; anemia 10% vs 15%, DM 24.2% vs 33.2%; AF 33.3% vs 40.2%; CKD 43.2% vs 45.3%, history of MI 4.1% vs 12.6%; stroke 6.5% vs 3.7%, COPD 5.7% vs 8.9%, respectively. NAFLD subgroup experienced complications with ACS 8.6% vs 3.1%, severe sepsis 24.6% vs 5%, ARF 44% vs 22.5%. NAFLD cohort had significantly higher mortality and worse clinical outcomes (Table 1). Conclusion Patients undergoing heart transplantation with co-existent NAFLD demonstrated significantly worse clinical outcomes and higher resource utilization. They were younger and less comorbid overall. NAFLD is associated with increased rates of acute complications, GIB, cardiac and respiratory failure. Detection and appropriate management of NAFLD in patients undergoing HTx would improve clinical results. More research is needed to describe long-term outcomes.

Liver transplantation and nonalcoholic steatohepatitis: the state of the art

Extrahepatic Organs in the Development of Non-Alcoholic Fatty Liver Disease in Liver Transplant Patients.

Extrahepatic organs in the development of non-alcoholic fatty liver disease in liver transplant patients

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management

Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation

Endoscopic Bariatric and Metabolic Therapies for Liver Disease: Mechanisms, Benefits, and Associated Risks

Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.

Short-term and long-term outcomes of liver transplantation using moderately and severely steatotic donor livers: A systematic review.

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Navigating Immune Cell Immunometabolism after Liver Transplantation

Current status of liver transplantation for non-B non-C liver cirrhosis and hepatocellular carcinoma

Metabolic Complications in Liver Transplantation Recipients: How We Can Optimize Long‐Term Survival

Hepatic steatosis after liver transplantation: a systematic review and meta-analysis

Surging Liver Transplantation for Nonalcoholic Steatohepatitis from 2000-2022: A National Database Study

Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research

Impact of living donor liver transplantation on long-term cardiometabolic and graft outcomes in cirrhosis due to nonalcoholic steatohepatitis

Evaluation of recipients with significant comorbidity - Patients with cardiovascular disease

The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease

A Comprehensive Review of Liver Allograft Fibrosis and Steatosis: From Cause to Diagnosis

Changing landscape of liver transplant in the United States- time for a new innovative way to define and utilize the "non-standard liver allograft"-a proposal

Higher Mortality And Resource Utilization In Patients Undergoing Cardiac Transplantation Affected By Non-alcoholic Fatty Liver Disease, Nation-Wide Study